Savara (SVRA) Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Do institutionals & insiders have more ownership in LGND or SVRA?

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 5.9% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media favor LGND or SVRA?

In the previous week, Savara had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 11 mentions for Savara and 4 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.33 beat Savara's score of 0.76 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer LGND or SVRA?

Ligand Pharmaceuticals received 253 more outperform votes than Savara when rated by MarketBeat users. Likewise, 70.39% of users gave Ligand Pharmaceuticals an outperform vote while only 66.89% of users gave Savara an outperform vote.

Company	Underperform	Outperform
Ligand Pharmaceuticals	Outperform Votes 554 70.39%	Underperform Votes 233 29.61%
Savara	Outperform Votes 301 66.89%	Underperform Votes 149 33.11%

Is LGND or SVRA more profitable?

Ligand Pharmaceuticals has a net margin of 29.68% compared to Savara's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 4.95% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	29.68%	4.95%	4.39%
Savara	N/A	-58.89%	-46.44%

Which has more risk & volatility, LGND or SVRA?

Ligand Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

Which has stronger earnings & valuation, LGND or SVRA?

Ligand Pharmaceuticals has higher revenue and earnings than Savara. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$181.49M	10.77	$52.15M	-$7.12	-14.23
Savara	N/A	N/A	-$54.70M	-$0.48	-6.10

Do analysts rate LGND or SVRA?

Ligand Pharmaceuticals currently has a consensus target price of $146.14, suggesting a potential upside of 44.28%. Savara has a consensus target price of $8.83, suggesting a potential upside of 201.48%. Given Savara's higher probable upside, analysts clearly believe Savara is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Savara	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Ligand Pharmaceuticals beats Savara on 14 of the 17 factors compared between the two stocks.